Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Jul 10;2(13):1522-1531.
doi: 10.1182/bloodadvances.2018019034.

Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia

Anthony S Stein  1 , Richard A Larson  2 , Andre C Schuh  3 , William Stevenson  4 , Ewa Lech-Maranda  5   6 , Qui Tran  7 , Zachary Zimmerman  7 , William Kormany  7 , Max S Topp  8
Affiliations
Clinical Trial

Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia

Anthony S Stein et al. Blood Adv. .

Abstract

In the phase 3 TOWER study, blinatumomab demonstrated an overall survival benefit over standard-of-care chemotherapy (SOC) in adults with relapsed or refractory (r/r) Philadelphia chromosome-negative (Ph-) B-precursor acute lymphoblastic leukemia (ALL). Nearly all patients in both treatment arms experienced an adverse event (AE), and the incidence rate of serious AEs was higher for blinatumomab. However, as treatment exposure differed between the 2 arms, we conducted an exploratory safety analysis comparing exposure-adjusted event rates (EAERs) of blinatumomab vs SOC. Analyses were conducted for all patients who received therapy (safety population). Patients received a median (range) of 2 cycles (1-9) of blinatumomab (N = 267) vs 1 cycle (1-4) of SOC (N = 109). Grade ≥3 AE rates were generally higher in cycle 1 of blinatumomab than in cycle 2 (76% vs 37%). After adjusting for time on treatment, EAERs of grade ≥3 were significantly lower for blinatumomab vs SOC overall (10.73 vs 45.27 events per patient-year; P < .001) and for events of clinical interest, including infections (1.63 vs 6.49 events per patient-year; P < .001), cytopenias (3.64 vs 20.07 events per patient-year; P < .001), and neurologic events (0.38 vs 0.95 events per patient-year; P = .008). The EAER of grade ≥3 cytokine-release syndrome was higher for blinatumomab than for SOC (0.16 vs 0 events per patient-year; P = .038). These data further support the role of blinatumomab as an efficacious and well-tolerated treatment option for patients with r/r Ph- ALL. This trial was registered at www.clinicaltrials.gov as #NCT02013167.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: A.S.S. received consulting fees and is a member of the speaker’s bureau for Amgen Inc. R.A.L received consulting fees from Amgen Inc. A.C.S. received consulting fees from Amgen Inc. W.S. received honoraria from Amgen Inc. E.L.-M. received consulting fees from Amgen Inc, Roche, and Janssen-Cilag. Q.T. is an employee of Amgen Inc. Z.Z. and W.K. are employees of and hold stock in Amgen Inc. M.S.T. received research grants from Amgen Inc, Gilead, Macrogenics, Roche, and Regeneron, as well as consulting fees from Amgen Inc, Roche, and Regeneron.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Patient disposition. Data cutoff was 4 January 2016. CR, complete remission; CRh, complete remission with partial hematologic recovery; CRi, complete remission with incomplete hematologic recovery.
Figure 2.
Figure 2.
Incidence of treatment-emergent AEs by treatment cycle. For (A) blinatumomab and (B) SOC.
See this image and copyright information in PMC

References

    1. Goldstone AH, Richards SM, Lazarus HM, et al. . In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111(4):1827-1833. - PubMed
    1. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29(5):532-543. - PubMed
    1. Nishiwaki S, Inamoto Y, Sakamaki H, et al. . Allogeneic stem cell transplantation for adult Philadelphia chromosome-negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission. Blood. 2010;116(20):4368-4375. - PubMed
    1. Fielding AK, Richards SM, Chopra R, et al. ; Eastern Cooperative Oncology Group. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109(3):944-950. - PubMed
    1. Tavernier E, Boiron JM, Huguet F, et al. ; Australasian Leukaemia and Lymphoma Group. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007;21(9):1907-1914. - PubMed

Publication types

Associated data